首页> 美国卫生研究院文献>Experimental Hematology Oncology >Long term efficacy and safety of Fludarabine Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

【2h】

Long term efficacy and safety of Fludarabine Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

机译：氟达拉滨环磷酰胺和利妥昔单抗方案联合90Y-ibritumomab替西坦巩固治疗复发性1和2级滤泡性淋巴瘤的长期疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundIn this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with ⁹⁰Yttrium- ibritumomab tiuxetan (⁹⁰Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were treated in a consolidation setting after having achieved complete (CR) or partial remission (PR) with Fludarabine, Cyclophosphamide and Rituximab (FCR).

机译：背景在这项回顾性研究中，我们研究了9例复发性滤泡性淋巴瘤（FL）患者中，使用^{90 钇-ibritumomab替西坦（^{90 Y-RIT）进行放射免疫治疗的有效性和安全性在用氟达拉滨，环磷酰胺和利妥昔单抗（FCR）实现完全（CR）或部分缓解（PR）后，在巩固治疗中进行治疗。}}

著录项

期刊名称 Experimental Hematology Oncology
作者
Francesco Pisani; Rosa Sciuto; Maria Laura Dessanti; Diana Giannarelli; Ramy Kayal; Sandra Rea; Francesco Marchesi; Mirella Marino;
展开▼
作者单位

展开▼
年(卷),期 2015(4),-1
年度 2015
页码 17
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Follicular lymphoma sup90/supY-ibritumomab tiuxetan Radioimmunotherapy;

机译：滤泡性淋巴瘤;sup 90 / sup Y-ibritumomab替西坦;放射免疫治疗;

相似文献

外文文献
中文文献
专利

1. Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma [J] . Francesco Pisani, Rosa Sciuto, Maria Laura Dessanti, Experimental Hematology Oncology . 2015,第1期

机译：氟达拉滨，环磷酰胺和利妥昔单抗方案联合90Y-ibritumomab替沙坦联合治疗复发性1和2级滤泡性淋巴瘤的长期疗效和安全性
2. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases [J] . Francesco Pisani, Carlo L Maini, Rosa Sciuto, Journal of experimental & clinical cancer research : . 2011,第1期

机译：FCR（氟达拉滨，环磷酰胺，利妥昔单抗）方案后加90钇伊贝单抗替沙坦巩固治疗复发的1级和2级滤泡性淋巴瘤：9例报告
3. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. [J] . Karmali R, Kassar M, Venugopal P, Clinical lymphoma, myeloma & leukemia . 2011,第6期

机译：氟达拉滨，米托蒽醌和利妥昔单抗，钇90 ibritumomab替uxtan联合维持利妥昔单抗作为滤泡或边缘区淋巴瘤患者的一线治疗的安全性和有效性。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. FCR (Fludarabine Cyclophosphamide Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases [O] . Francesco Pisani, Carlo Ludovico Maini, Rosa Sciuto, 2011

机译：FCR（氟达拉滨环磷酰胺利妥昔单抗）方案后加90钇伊贝单抗替丁塞坦巩固治疗复发的1级和2级滤泡性淋巴瘤：9例报告
6. Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma [O] . 2015

机译：氟达拉滨，环磷酰胺和利妥昔单抗方案联合Y-ibritumomab替沙坦联合治疗复发性1和2级滤泡性淋巴瘤的长期疗效和安全性

Long term efficacy and safety of Fludarabine Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅